Ciotti M, Chen F, Rubaltelli F F, Owens I S
Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 9S-242, Bethesda, Maryland 20892-1830, USA.
Biochim Biophys Acta. 1998 Jul 1;1407(1):40-50. doi: 10.1016/s0925-4439(98)00030-1.
Mutations at the bilirubin UDP-glucuronosyltransferase (transferase) gene in a severely hyperbilirubinemic Crigler-Najjar (CN) type I individual was compared with that in a moderately hyperbilirubinemic CN II individual. The CN-I (CF) patient in this study sustained a TATA box insertional mutation which was paired with a coding defect at the second allele, unlike all coding defects previously seen in CN-I patients. The sequence of the mutant TATA box, [A(TA)8A], also seen in the CN-II patient, was compared with that at the wild-type box, [A(TA)7A]. Transcriptional activity with [A(TA)8A] was 10-15% that with the wild-type box when present in the -1.7 kb upstream regulatory region (URR) of the bilirubin transferase UGT1A1 gene which was fused to the chloramphenicol acetyl transferase reporter gene, pCAT 1.7H, and transfected into HepG2 cells. Also, a construct with a TA deletion, [A(TA)6A], was prepared and used as a control; transcriptional activity was 65% normal. The coding region defect, R336W, seen in CF (CN-I) was placed in the bilirubin transferase UGT1A1 [HUG-Br1] cDNA, and its corresponding protein was designated UGT1A132. The UGT1A132 protein supported 0-10% normal bilirubin glucuronidation when expressed in COS-1 cells. The I294T coding defect seen at the second allele in SM (CN-II) generated the UGT1A1*33 mutant protein which supported 40-55% normal activity with a normal Km (2.5 microM) for bilirubin. The hyperbilirubinemia seen in SM decreased in response to phenobarbital treatment, unlike that seen in CF. Parents of the patients were carriers of the respective mutations uncovered in the offspring. The TATA box mutation paired with a deleterious missense mutation is, therefore, completely repressive in the CN-I patient, and is responsible for a lethal genotype/phenotype; but when homozygous, i.e. paired with itself, as previously reported in the literature, it is far less repressive and generates the mild Gilbert's phenotype.
将一名严重高胆红素血症的克里格勒 - 纳贾尔(CN)I型个体的胆红素UDP - 葡萄糖醛酸基转移酶(转移酶)基因突变与一名中度高胆红素血症的CN II型个体的该基因突变进行了比较。本研究中的CN - I(CF)患者存在一个TATA框插入突变,该突变与第二个等位基因上的编码缺陷配对,这与之前在CN - I患者中看到的所有编码缺陷不同。在CN - II患者中也发现的突变TATA框序列[A(TA)8A],与野生型框[A(TA)7A]的序列进行了比较。当[A(TA)8A]存在于与氯霉素乙酰转移酶报告基因pCAT 1.7H融合并转染到HepG2细胞中的胆红素转移酶UGT1A1基因的 - 1.7 kb上游调控区(URR)时,其转录活性是野生型框的10 - 15%。此外,制备了一个TA缺失的构建体[A(TA)6A]并用作对照;转录活性为正常的65%。在CF(CN - I)中看到的编码区缺陷R336W被置于胆红素转移酶UGT1A1 [HUG - Br1] cDNA中,其相应的蛋白质被命名为UGT1A132。当在COS - 1细胞中表达时,UGT1A132蛋白的胆红素葡萄糖醛酸化活性为正常的0 - 10%。在SM(CN - II)的第二个等位基因中看到的I294T编码缺陷产生了UGT1A1*33突变蛋白,该蛋白对胆红素具有正常的Km(2.5 microM),其活性为正常的40 - 55%。与CF中看到的情况不同,SM中看到的高胆红素血症在苯巴比妥治疗后有所减轻。患者的父母是在后代中发现的各自突变的携带者。因此,与有害错义突变配对的TATA框突变在CN - I患者中具有完全抑制作用,并导致致死性基因型/表型;但如文献中先前报道的那样,当它是纯合子时,即与自身配对时,其抑制作用要小得多,并产生轻度的吉尔伯特综合征表型。